Is AMBUJACEM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of AMBUJACEM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AMBUJACEM (₹504.95) is trading below our estimate of fair value (₹590.39)
Significantly Below Fair Value: AMBUJACEM is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AMBUJACEM?
Key metric: As AMBUJACEM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for AMBUJACEM. This is calculated by dividing AMBUJACEM's market cap by their current
earnings.
What is AMBUJACEM's PE Ratio?
PE Ratio
41.8x
Earnings
₹29.74b
Market Cap
₹1.24t
AMBUJACEM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue
3.8x
Enterprise Value/EBITDA
22.2x
PEG Ratio
1.5x
Price to Earnings Ratio vs Peers
How does AMBUJACEM's PE Ratio compare to its peers?
Price-To-Earnings vs Industry: AMBUJACEM is expensive based on its Price-To-Earnings Ratio (41.8x) compared to the Indian Basic Materials industry average (37.8x).
Price to Earnings Ratio vs Fair Ratio
What is AMBUJACEM's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
AMBUJACEM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
41.8x
Fair PE Ratio
46.2x
Price-To-Earnings vs Fair Ratio: AMBUJACEM is good value based on its Price-To-Earnings Ratio (41.8x) compared to the estimated Fair Price-To-Earnings Ratio (46.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
The above table shows the analyst AMBUJACEM forecast and predictions for the stock price in 12 month’s time.
Date
Share Price
Average 1Y Price Target
Dispersion
High
Low
1Y Actual price
Analysts
Current
₹504.95
₹647.78
+28.3%
15.6%
₹950.00
₹410.00
n/a
37
Nov ’25
₹582.45
₹654.35
+12.3%
16.2%
₹950.00
₹410.00
n/a
37
Oct ’25
₹632.45
₹679.75
+7.5%
15.8%
₹835.00
₹410.00
n/a
36
Sep ’25
₹617.05
₹681.42
+10.4%
15.6%
₹835.00
₹410.00
n/a
36
Aug ’25
₹664.00
₹675.47
+1.7%
16.5%
₹840.00
₹410.00
n/a
36
Jul ’25
₹695.00
₹650.68
-6.4%
17.2%
₹840.00
₹410.00
n/a
37
Jun ’25
₹634.05
₹626.38
-1.2%
16.9%
₹840.00
₹410.00
n/a
37
May ’25
₹619.90
₹580.80
-6.3%
19.8%
₹950.00
₹350.00
n/a
35
Apr ’25
₹621.50
₹579.37
-6.8%
20.3%
₹950.00
₹350.00
n/a
35
Mar ’25
₹617.60
₹564.83
-8.5%
19.7%
₹950.00
₹350.00
n/a
35
Feb ’25
₹565.05
₹537.52
-4.9%
14.4%
₹660.00
₹350.00
n/a
33
Jan ’25
₹534.30
₹470.39
-12.0%
13.7%
₹600.00
₹325.00
n/a
33
Dec ’24
₹442.00
₹465.26
+5.3%
13.2%
₹600.00
₹325.00
n/a
35
Nov ’24
₹406.65
₹463.42
+14.0%
14.0%
₹600.00
₹300.00
₹582.45
36
Oct ’24
₹424.80
₹466.89
+9.9%
13.7%
₹602.00
₹300.00
₹632.45
36
Sep ’24
₹433.90
₹471.54
+8.7%
13.4%
₹602.00
₹300.00
₹617.05
39
Aug ’24
₹461.55
₹437.76
-5.2%
13.2%
₹570.00
₹300.00
₹664.00
37
Jul ’24
₹425.90
₹435.19
+2.2%
13.7%
₹570.00
₹300.00
₹695.00
36
Jun ’24
₹429.25
₹431.41
+0.5%
12.9%
₹570.00
₹300.00
₹634.05
37
May ’24
₹396.50
₹432.14
+9.0%
12.2%
₹570.00
₹340.00
₹619.90
36
Apr ’24
₹365.55
₹439.81
+20.3%
13.0%
₹570.00
₹340.00
₹621.50
36
Mar ’24
₹353.60
₹440.09
+24.5%
13.1%
₹570.00
₹340.00
₹617.60
34
Feb ’24
₹334.10
₹495.77
+48.4%
19.2%
₹752.00
₹305.00
₹565.05
35
Jan ’24
₹524.10
₹490.03
-6.5%
20.0%
₹752.00
₹305.00
₹534.30
37
Dec ’23
₹580.95
₹488.95
-15.8%
19.9%
₹752.00
₹305.00
₹442.00
37
Nov ’23
₹544.05
₹479.65
-11.8%
21.0%
₹752.00
₹305.00
₹406.65
37
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.